Physician profile
Kimalisa Locklear
NPI 1306482500
$34,495.83
in general payments reported to CMS, 2019-2025
28 companies · $10K in 2025
The $10K reported for 2025 was more than what 99% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $538 · 2022: $444 · 2023: $12K · 2024: $12K · 2025: $10K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Long Term Medical Supply Or Device Loan: $30K · Food and Beverage: $2,009 · Travel and Lodging: $962 · Education: $100.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Long Term Medical Supply Or Device Loan | $30,443.33 |
| Food and Beverage | $2,008.90 |
| Travel and Lodging | $961.97 |
| Education | $100.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Angiodynamics, INC. | $30,563.21 | 2021-2025 | Auryon Laser System 100-120 Vac, Venacure 1470 Pro |
| Bard Peripheral Vascular, INC. | $1,190.40 | 2024 | Venclose Maven Catheter |
| Janssen Pharmaceuticals, INC | $412.83 | 2021-2024 | Xarelto |
| Merck Sharp & Dohme LLC | $343.39 | 2021-2025 | Verquvo |
| Amgen INC. | $305.11 | 2021-2025 | Repatha |
| Pfizer INC. | $241.34 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $193.05 | 2021-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $185.86 | 2021-2025 | |
| Novo Nordisk INC | $176.40 | 2022-2023 | Ozempic, Saxenda, Wegovy |
| Novartis Pharmaceuticals Corporation | $160.77 | 2021-2024 | |
| Scpharmaceuticals INC. | $160.20 | 2023-2024 | |
| Astrazeneca Pharmaceuticals Lp | $85.62 | 2021-2023 | Farxiga |
| Organogenesis INC. | $85.42 | 2024-2025 | Puraply Wound Matrix, Apligraf |
| E.R. Squibb & Sons, L.L.C. | $44.50 | 2022-2024 | Eliquis, Camzyos |
| Alnylam Pharmaceuticals INC. | $40.54 | 2023-2024 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kiniksa Pharmaceuticals, Ltd. | $37.40 | 2021-2023 | Arcalyst |
| Lexicon Pharmaceuticals, INC. | $33.22 | 2023 | Inpefa |
| Cashflow Solutions, LLC | $31.20 | 2025 | Lympha Press Optimal Plus(US) Bt, Pcd-52 737a (US) White, Pcd-51 731a (US) - White |
| Vital Connect, INC | $28.35 | 2025 | Vitalpatch Rtm |
| Actelion Pharmaceuticals US, INC. | $25.54 | 2023 | Uptravi, Opsumit |
| Boston Scientific Corporation | $24.56 | 2022 | |
| Kiniksa Pharmaceuticals International, Plc | $22.49 | 2024 | Arcalyst |
| Baxter Healthcare | $20.27 | 2023 | Hillrom - Carnation Ambulatory Monitor |
| Amarin Pharma, INC. | $20.26 | 2021 | |
| Edwards Lifesciences Corporation | $19.04 | 2023 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Smith+Nephew, INC. | $18.87 | 2022 | |
| Kestra Medical Technology Services, INC. | $13.30 | 2024 | Assure Wcd |
| Inspire Medical Systems, INC. | $12.69 | 2023 | Inspire |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kimalisa Locklear listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.